Summary
- Pfizer is a proven pioneer of therapeutics for HIV infection, autoimmune, cardiovascular and gastrointestinal diseases, as well as hematological and oncological ailments.
- At the end of Q4 2018, Pfizer reported a revenue increase of $274M, or 2%, compared to Q4 2017.
- Pfizer is progressing effectively in its NAFLD and NASH franchise pipeline, comprising diacylglycerol O-Acyltransferase 2 inhibitor, acetyl-CoA carboxylase inhibitor and a ketohexokinase inhibitor.
- In Q4 2018, Pfizer announced a non-exclusive clinical development agreement with Novartis for combination therapeutic approach to NASH. I do not visualize the clinical agreement as a game changer.
- For reasons which I elaborate on in text, its combination approach with in-house candidates are potential clinical successes.
- Looking for more? I update all of my investing ideas and strategies to members of Liver Therapy Forum (LTF). Get started today »
My Outlook
Pfizer Inc. (PFE), a large-cap ($245B) global biopharmaceutical company, gained pharmaceutical celebrity status when sildenafil citrate marketed globally as Viagra was approved in 1998. Obviously, Pfizer is more than man-helper since it is also a heart-restorer with the development of the blockbuster cardiovascular drug, Lipitor.
Lipitor is the most recognized statin drug used clinically to lower bad cholesterol, LDL-C. Pfizer’s therapeutic portfolio comprise drugs/candidates for several diseases, including HIV/AIDS, oncology, immunology, autoimmunity. Pfizer is also developing small drug molecules targeting the fibrotic disease, NASH (focus of this article).
